IRIS
STAROPOLI, Nicoletta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 258
EU - Europa 195
AS - Asia 120
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 576
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 249
IT - Italia 132
SG - Singapore 88
CN - Cina 19
GB - Regno Unito 16
DE - Germania 12
SE - Svezia 10
CA - Canada 9
RU - Federazione Russa 9
HK - Hong Kong 8
NL - Olanda 6
FR - Francia 3
AT - Austria 2
CZ - Repubblica Ceca 2
IN - India 2
PK - Pakistan 2
AU - Australia 1
CL - Cile 1
EU - Europa 1
FI - Finlandia 1
ID - Indonesia 1
PT - Portogallo 1
UA - Ucraina 1
Totale 576
Salva come PNG Salva come JPEG
Città #
Chandler 44
Singapore 33
Chicago 20
Santa Clara 20
London 16
Milan 16
Catanzaro 12
Rome 11
Ashburn 10
Lawrence 10
Princeton 10
Hong Kong 8
Wilmington 8
Ottawa 7
Parma 7
Naples 6
Boardman 5
Beijing 4
Ercolano 4
Melito di Porto Salvo 4
Los Angeles 3
Moscow 3
Nuremberg 3
Redmond 3
Santo Stefano di Rogliano 3
Bisignano 2
Catania 2
Cavallino 2
Des Moines 2
Esslingen am Neckar 2
Jiaxing 2
Lahore 2
Marcianise 2
Mountain View 2
Olomouc 2
Reggio Calabria 2
Romainville 2
San Nicola Manfredi 2
Serra San Bruno 2
Shenzhen 2
Spezzano della Sila 2
St Petersburg 2
Washington 2
West Lafayette 2
Acri 1
Afragola 1
Amsterdam 1
Augusta 1
Berlin 1
Buffalo 1
Canberra 1
Chelyabinsk 1
Clearwater 1
Cosenza 1
Gatchina 1
Guangzhou 1
Gunzenhausen 1
Helsinki 1
Houston 1
Landshut 1
Maastricht 1
Manassas 1
Marion 1
Melito di Napoli 1
Montalto Uffugo 1
Montreal 1
Mumbai 1
Munich 1
Norwalk 1
Oristano 1
Pachino 1
Palermo 1
Phoenix 1
Quanzhou 1
Queluz 1
Saint Louis 1
Seattle 1
Settingiano 1
Shanghai 1
Sorrento 1
Squillace 1
Toronto 1
Yekaterinburg 1
Totale 347
Salva come PNG Salva come JPEG
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 51
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 39
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 38
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 35
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 33
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 32
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 32
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 31
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 30
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 29
Ramucirumab In Gastric Cancer Treatment: An Economic Evaluation 29
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 29
Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations 28
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 28
Economic Evaluation Of A New Non-Antibiotic First-line Treatment Of Recurrent Urinary Tract Infections 27
Prevalence of Non-Erosive Esophageal Phenotypes in children: a European multicenter study 20
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 20
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity 12
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 10
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 9
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 9
Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma 9
Cardiotoxicity of anti-HER2 drugs in the treatment of metastatic breast cancer: Case report 8
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 7
LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation 7
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis 5
Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) 4
Why Do You Treat pCR Patient With Pertuzumab and Trastuzumab? 4
The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis 3
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program 3
First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis 3
Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper 2
Totale 626
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.295
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.295
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206 0 0 0 0 0 0 0 0 0 0 1 5
2020/202127 3 0 0 2 3 3 1 0 5 9 1 0
2021/202244 0 0 1 17 0 2 0 8 4 8 2 2
2022/2023171 22 9 5 8 14 13 4 7 25 28 31 5
2023/2024135 41 10 12 6 7 25 1 1 0 7 13 12
2024/2025240 31 13 8 7 20 77 15 19 42 8 0 0
Totale 626